Neogenesis Biotech participated in the BIO Asia–Taiwan 2026 partnering program, engaging in one-on-one meetings with international partners from the biotech, pharmaceutical, medical, and investment sectors to share the latest developments in AI Cell Report, precision cell assessment, and companion diagnostics, while actively expanding global collaboration opportunities.

BIO Asia–Taiwan is a premier platform for the biotech industry in Asia, attracting biotech companies, medical institutions, pharmaceutical firms, investment organizations, and research units from around the world each year.

This year, Aprinoia Biotech participated in the conference's Partnering program, engaging in one-on-one discussions with various domestic and international companies to share our technical achievements in AI cell analysis, precision cell assessment, and regenerative medicine, while exploring future collaboration opportunities.

Focusing on AI and Precision Cell Assessment

Key highlights of these discussions included:

• AI Cell Report intelligent cell analysis platform
• Precision Cell Assessment
• Companion Diagnostics
• Regenerative medicine and cell therapy applications
• Clinical research and international collaboration models

Through these business meetings, Aprinoia Biotech held in-depth discussions with partners from various fields regarding technical applications, market demands, and future directions for collaboration.

‍